Takeda receives u.s. fda approval of fruzaqla™ (fruquintinib) for previously treated metastatic colorectal cancer

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved fruzaqla™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mcrc) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vegf therapy, and, if ras wild-type and medically appropriate, an anti-egfr therapy. fruzaqla is the first and only selective i.
TAK Ratings Summary
TAK Quant Ranking